NEW YORK--(BUSINESS WIRE)--The Rosen Law Firm, P.A., a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Accelerate Diagnostics, Inc. (Nasdaq:AXDX) resulting from allegations that Accelerate Diagnostics may have issued materially misleading business information to the investing public.
On February 18, 2015, Seeking Alpha published an article asserting that Accelerate Diagnostics falsely claimed that it had developed a technique for diagnosing pathogens in a blood sample without a need for using a blood culture. In reality, the test required a blood culture, a fact that significantly reduced the value of the technology. On this news, shares of Accelerate Diagnostics fell $4.04 per share or over 18% to close at $18.05 per share on February 20, 2015, damaging investors.
The Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Accelerate Diagnostics investors. If you purchased shares of Accelerate Diagnostics and wish to join the class action and recover your losses, please visit the website at http://www.rosenlegal.com/cases-546.html for more information. You may also contact Phillip Kim or Jonathan Stern of The Rosen Law Firm toll free at 866-767-3653 or via email at email@example.com or firstname.lastname@example.org.
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.